A blood test for colon cancer performed well in a study published Wednesday, offering a new kind of screening for a leading cause of cancer deaths.
The test looks for DNA fragments shed by tumor cells and precancerous growths. It’s already for sale in the U.S. for $895, but has not been approved by the Food and Drug Administration and most insurers do not cover it. The maker of the test, Guardant Health, anticipates an FDA decision this year.
In the study, the test caught 83% of the cancers but very few of the precancerous growths found by colonoscopy, the gold standard for colon cancer screening. Besides spotting tumors, colonoscopies can prevent the disease by removing precancerous growths called polyps.
But some people avoid the exam because of the hassle of getting time off work or the day-ahead preparation that involves drinking a strong laxative to empty the bowels.
Cruise worker 'murders newborn son on board ship': Shocked co
Evan Mobley has huge block in final seconds as Cavaliers hold off Banchero, Magic 104
Duane Eddy, twangy guitar hero of early rock, dead at age 86
Police fatally shoot a man who sliced an officer's face during a scuffle
Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire
Twins center fielder Byron Buxton leaves game against White Sox with sore right knee
Gisele Bundchen exudes sporty chic in an all
Stuart Fairchild's sensational catch robs Manny Machado of a 3
Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
JANE GREEN: The shameful truth about Barbra Streisand's acid
Nadal returns to Roland Garros to practice amid doubts over fitness and form
Georgia governor signs law requiring jailers to check immigration status of prisoners